Tailored Dc Induce Protective Hiv-1 Specific Polyfunctional Cd8+ T Cells in the Lymphoid Tissue From Humanized BLT Mice

Calvet‐Mirabent, Marta; Dt, Claiborne; Déruaz, Maud; Tanno, Serah; Serra, Carla; Delgado‐Arévalo, Cristina; Sánchez‐Cerrillo, Ildefonso; Santos, De Los; Sanz, Jesús; García‐Fraile, Lucio; Sánchez‐Madrid, Francisco; Alfranca, Arántzazu; Ma, Muñoz-Fernández; Allen, Todd M.; Mj, Buzón; Balazs, Alejandro B.; Vrbanac,; Martín‐Gayo, Enrique

doi:10.1101/2021.06.30.450486

Cited by 2 publications

(3 citation statements)

References 57 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TANK‐binding kinase 1 (TBK1) could be used to modulate the intrinsic immune activation of DCs against HIV‐1. TBK1‐primed DC‐vaccinated mice had a higher proportion of less depleted CD4+ T cells after HIV‐1 infection, which may be beneficial for subsequent vaccine studies 153 . In another study, the PolyI: C and STING were used as agonists on DC induction, and the addition of the adjuvant combination improved the expression of IL‐12, IFN‐β, and especially TBK‐1 phosphorylation on DCs.…”

Section: Humanized Mouse Modelsmentioning

confidence: 99%

“…TBK1‐primed DC‐vaccinated mice had a higher proportion of less depleted CD4+ T cells after HIV‐1 infection, which may be beneficial for subsequent vaccine studies. 153 In another study, the PolyI: C and STING were used as agonists on DC induction, and the addition of the adjuvant combination improved the expression of IL‐12, IFN‐β, and especially TBK‐1 phosphorylation on DCs. This characteristic increased cytokine capacity to activate HIV‐1‐specific CD8+ T cells, contributing to less CD4+ T‐cell depletion.…”

Section: Humanized Mouse Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

Wang,

Li,

Lin

et al. 2023

Anim Models and Exp Med

View full text Add to dashboard Cite

Patient‐derived tumor xenograft (PDX) models, a method involving the surgical extraction of tumor tissues from cancer patients and subsequent transplantation into immunodeficient mice, have emerged as a pivotal approach in translational research, particularly in advancing precision medicine. As the first stage of PDX development, the patient‐derived orthotopic xenograft (PDOX) models implant tumor tissue in mice in the corresponding anatomical locations of the patient. The PDOX models have several advantages, including high fidelity to the original tumor, heightened drug sensitivity, and an elevated rate of successful transplantation. However, the PDOX models present significant challenges, requiring advanced surgical techniques and resource‐intensive imaging technologies, which limit its application. And then, the humanized mouse models, as well as the zebrafish models, were developed. Humanized mouse models contain a human immune environment resembling the tumor and immune system interplay. The humanized mouse models are a hot topic in PDX model research. Regarding zebrafish patient‐derived tumor xenografts (zPDX) and patient‐derived organoids (PDO) as promising models for studying cancer and drug discovery, zPDX models are used to transplant tumors into zebrafish as novel personalized medical animal models with the advantage of reducing patient waiting time. PDO models provide a cost‐effective approach for drug testing that replicates the in vivo environment and preserves important tumor‐related information for patients. The present review highlights the functional characteristics of each new phase of PDX and provides insights into the challenges and prospective developments in this rapidly evolving field.

show abstract

Section: Humanized Mouse Modelsmentioning

confidence: 99%

Section: Humanized Mouse Modelsmentioning

confidence: 99%

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

Wang,

Li,

Lin

et al. 2023

Anim Models and Exp Med

View full text Add to dashboard Cite

show abstract

“…The vaccine contains peptides selected for predicted T-cell immunogenicity, compared with a second group of peptides selected for antibody responses against linear epitopes. Peptide antigens are combined with either of two different adjuvants known for eliciting potent T-cell responses, poly(I:C) (28) and the STING agonist BI-1387466 (29) .…”

Section: Introductionmentioning

confidence: 99%

A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease

Baxter

Anderson

Taft-Benz

et al. 2022

Preprint

View full text Add to dashboard Cite

There is significant interest in T-cell mediated immunity against SARS-CoV-2. Both vaccination and infection have been observed to elicit durable T-cell responses against the virus. The classical role of CD4+ T-cell responses in coordinating humoral immunity is well understood but it is less clear to what degree, if any, T-cell responses play a direct protective role against infection In this study we vaccinated BALB/c mice with peptides derived from the SARS-CoV-2 proteome designed to either elicit T-cell responses or B-cell responses against linear epitopes. These peptides were administered in combination with either of two adjuvants, poly(I:C) and the STING agonist BI-1387466. Both adjuvants consistently elicited responses against the same peptides, preferentially from the group selected for predicted T-cell immunogenicity. The magnitude of T-cell responses was, however, significantly higher with BI-1387466 compared with poly(I:C). Neither adjuvant group, however, provided any protection against infection with the murine adapted virus SARS-CoV-2-MA10 or from disease following infection.

show abstract

Tailored Dc Induce Protective Hiv-1 Specific Polyfunctional Cd8+ T Cells in the Lymphoid Tissue From Humanized BLT Mice

Cited by 2 publications

References 57 publications

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research

A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease

Contact Info

Product

Resources

About